BioPort anthrax vaccine
Executive Summary
Department of Defense is in negotiations with BioPort to purchase anthrax vaccine after Jan. 31 licensure of Biothrax. Approval clears 370,000 doses; BioPort's production capacity for FY 2002 is 2 mil. doses and 3 mil.-8 mil. doses for FY 2003, HHS said. FDA completed inspection of the Hollister-Steir filling facility in Spokane, Wash. Jan. 10; pre-approval of BioPort's Lansing, Mich. manufacturing facility was granted Dec. 19. Updated labeling includes new postmarketing safety data...